Veracyte company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

veracyte.com

Founded Year

2008

Stage

IPO | IPO

Total Raised

$79M

Date of IPO

10/30/2013

Market Cap

1.25B

Stock Price

18.37

Revenue

$0000 

About Veracyte

Veracyte is a molecular diagnostics company in the field of molecular cytology. The company is focused on discovering, developing and commercializing molecular diagnostic solutions that enable physicians to make more informed treatment decisions at an early stage in patient treatment, thus helping patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte's first product – the Afirma Thyroid FNA Analysis – combines specialized cytopathology assessment with the Afirma Gene Expression Classifier, a genomic test that clarifies inconclusive thyroid nodule results as benign or suspicious for cancer.

Veracyte Headquarter Location

6000 Shoreline Court Suite 300

South San Francisco, California, 94080,

United States

650-243-6350

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Veracyte

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Veracyte is included in 2 Expert Collections, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

O

Omics

1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Veracyte Patents

Veracyte has filed 47 patents.

The 3 most popular patent topics include:

  • Rare diseases
  • Syndromes
  • Lung disorders
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/25/2018

1/4/2022

Molecular biology, Genetics, DNA, Biotechnology, Molecular biology techniques

Grant

Application Date

6/25/2018

Grant Date

1/4/2022

Title

Related Topics

Molecular biology, Genetics, DNA, Biotechnology, Molecular biology techniques

Status

Grant

Latest Veracyte News

Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment

May 16, 2022

Findings Presented at ATS 2022 May 16, 2022 04:17 PM Eastern Daylight Time SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Veracyte, Inc. (Nasdaq: VCYT) today announced new data showing that its Percepta Nasal Swab test accurately assesses lung cancer risk among current and former smokers with lung nodules, regardless of their smoking history burden and whether they are considered high risk for lung cancer based on U.S. Preventive Services Task Force (USPSTF) screening criteria. The findings were presented today at the American Thoracic Society 2022 International Conference (ATS 2022), being held in San Francisco. “Our analysis showed that the nasal genomic classifier performed similarly well in patients across the spectrum of tobacco-related risk," said Carla R. Lamb, M.D., a pulmonary and critical care physician and Director of Interventional Pulmonary at Lahey Hospital & Medical Center who presented the study findings. “These findings suggest that the test can be reliably used in ever-smokers whose lung nodules were found incidentally, as well as through screening.” For the study, researchers evaluated data from a subset of 291 current and former smokers with lung nodules who were part of the original clinical validation study for the Percepta Nasal Swab test. Among these individuals, 213 (73%) met USPSTF screening criteria (pack years ≥20, years since quit <15, age 50-80 years), while 78 (27%) did not. Researchers compared the performance of the classifier in the two patient subsets and found no statistically significant differences in the classifier’s sensitivity and specificity between the two groups. Specifically, among those who met the USPSTF criteria for lung cancer screening, the test’s sensitivity was 96% when it identified a nodule as low risk for cancer and its specificity was 94% when it identified it as high risk. Among patients who did not meet the USPSTF lung cancer screening eligibility, the test’s sensitivity was 100% when it identified nodules as low risk for cancer and its specificity was 88% when it identified them as high risk. “The data presented today reinforce the important role that the Percepta Nasal Swab classifier may play in helping to guide next steps for current and former smokers with lung nodules – including those who may be considered low risk based on their smoking history burden,” said Giulia C. Kennedy, Ph.D., Veracyte’s global chief scientific officer and chief medical officer. “More accurate, timely diagnosis of these patients could ultimately lead to fewer unnecessary diagnostic procedures among those without lung cancer, and timelier treatment for those with the disease.” The Percepta Nasal Swab test’s performance in classifying lung cancer risk has previously been demonstrated, and it is being made available to a limited number of sites as the company develops the clinical utility evidence to support reimbursement. Also at ATS 2022, Veracyte will host two Learning Theater events during which leading physicians will discuss their experiences incorporating novel genomic testing into the diagnoses of interstitial lung disease (ILD) and lung cancer, respectively: Title: Integrating novel genomic data to improve ILD diagnostic and prognostic confidence Presenter: Lisa H. Lancaster, M.D. Date/Time: May 17, 12:30 p.m. PT Location: Mini Theater #2

Veracyte Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Veracyte Rank

  • When was Veracyte founded?

    Veracyte was founded in 2008.

  • Where is Veracyte's headquarters?

    Veracyte's headquarters is located at 6000 Shoreline Court, South San Francisco.

  • What is Veracyte's latest funding round?

    Veracyte's latest funding round is IPO.

  • How much did Veracyte raise?

    Veracyte raised a total of $79M.

  • Who are the investors of Veracyte?

    Investors of Veracyte include National Science Foundation.

  • Who are Veracyte's competitors?

    Competitors of Veracyte include Stratipath, numares, GANYMED Pharmaceuticals, Activate Immunotherapy, Ikaria and 8 more.

You May Also Like

O
Oncology Research Therapeutics

Oncology Research Therapeutics, Inc. is dedicated to providing and discovering cancer diagnostics that improve the lives of patients suffering from a wide array of cancers. They also provide R&D services that improve drug development for the Biotech and Pharmaceutical industries.

T
TenX Biopharma

TenX is a biopharmaceutical company focused on late stage development and launch of novel cancer products.

P
Proacta

Proacta is a clinical-stage, biopharmaceutical company focused on addressing unmet needs in the field of cancer with current efforts directed towards the development of hypoxia-activated prodrugs that target treatment-resistant cancer cells.

E
Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

O
Occam BioLabs

Occam BioLabs is a company engaged in developing technologies for detection and quantification of biomolecules. The company is focused on three general areas of research and development: design and prototyping of electro-optical devices for analysis of biological samples, developing analytic reagents and kits for emergent biomedical fields, providing expertise services for assay optimization including high-throughput quantification in the pharmaceutical industry.

O
Onyvax

Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines. Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.